BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the CE-IVDD certification of the BD COR™ System in Europe. The high throughput solution for infectious disease diagnostics sets a new standard in automation for molecular testing in core laboratories and other large centralized laboratories.
You are here
To explain a person's actions in the present, it sometimes helps to understand their past, including where they come from and how they were raised. This is also true of tumors. Delving into a tumor's cellular lineage, a Ludwig Cancer Research study shows, can reveal weaknesses to target for customized therapies.
The findings, detailed in the April 24 issue of the journal Nature, also illustrate how knowledge of the biochemistry and microenvironment of the tissue from which a tumor arises can help predict the genetic alterations its cancer cells are likely to undergo.
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machines identify cancers--and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.
Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer (NSCLC). Assessing the level of programmed death ligand 1 (PD-L1) expressed by a tumor can help clinicians determine how the patient should be treated. A report in The Journal of Molecular Diagnostics describes a novel and rapid approach for quantifying PD-L1 expression levels in tumors that requires only small amounts of tissue that can be collected using minimally-invasive bronchoscopy techniques.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer screening - especially for low-income women who are overdue for testing.
A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or "plastic antibodies." NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells. This approach could lead to a paradigm shift in the development of new methods for cancer treatment.
Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
TISSUE DIAGNOSTICS SUCCESSFULLY TESTED
Today physicians are still severely hampered by the lack of precision of the needle tip location during a biopsy. Looking at lung cancers, 25% of the diagnoses suffer a false negative outcome through traditional biopsy methods. In the future, this can be avoided: for the first time, the European project InSPECT developed miniature spectrometers with integrated light sources enabling guided sensing.
esearchers at the UCLA Samueli School of Engineering have demonstrated that deep learning, a powerful form of artificial intelligence, can discern and enhance microscopic details in photos taken by smartphones. The technique improves the resolution and color details of smartphone images so much that they approach the quality of images from laboratory-grade microscopes.
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.